WALTHAM, Mass.--(BUSINESS WIRE)--Nomir Medical Technologies, announced today the presentation of positive in vitro and in vivo human data for its Noveon® direct optical energy device for treating onychomycosis (toe nail fungus). The studies demonstrated that treatment with the Noveon resulted in complete photo-inactivation of the fungi that cause onychomycosis at safe energy densities and temperatures. Nomir will present the data at the New Cardiovascular Horizons “Wound Management of the Diabetic Foot and Wound Healing” conference in New Orleans. The abstract is available online at http://www.newcvhorizons.com/uploads/Abstract_701].pdf. A pivotal product registration trial for Noveon for the onychomycosis indication is currently underway.
